Info

Intarcia Therapeutics, Inc., incorporated in June 1995, is a biopharmaceutical company with an approach to acquire, develop and commercialize therapeutic products for the treatment of cancer and infectious diseases. The Company is developing atamestane, its aromatase inhibitor, in combination with toremifene, an approved estrogen receptor blocker, for the treatment of hormone-dependent breast cancer in postmenopausal women. During the year ended December 31, 2004, Intarcia Therapeutics, Inc. was in Phase III clinical development with this combination for the initial or first line treatment of hormone-dependent advanced (metastatic or locally advanced) breast cancer in postmenopausal women. It is developing omega DUROS, a subcutaneous implant designed to deliver its omega interferon, for the treatment of hepatitis C. The Company has completed a Phase II clinical trial of omega interferon.